alpha-Bisabolol oxide B is a recurring chamomile sesquiterpene oxide found most often in German chamomile identity and chemotype papers rather than in dedicated pharmacology studies. Live sources support it strongly as a real and often notable part of chamomile volatile profiles, but the isolated-compound bioactivity literature remains thin. For AromaForge it is best framed as a chemistry-first constituent with limited direct mechanism evidence and mostly mixture-level or in silico biological context.
Chemical identity and composition
NIST lists alpha-bisabolol oxide B as C15H26O2 and CAS 26184-88-3, while PubChem also maintains a bisabolol oxide B record with the same formula. Open chamomile composition papers repeatedly report oxide B alongside oxide A, alpha-bisabolol, bisabolone oxide A, and chamazulene. In the Estonia paper it appears at 8-12%, and a 2025 Bulgarian full-text study reported 10.8-13.7% in two German chamomile oils, making it one of the more stable chamomile sesquiterpene markers.
Aroma and practical use
- Use the recorded soft, herbal, woody, chamomile-like, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The Estonia chamomile composition paper identified bisabolol oxide B at 8-12% and placed it among the major constituents of the studied oils.
This supports oxide B as a stable component of oxide-rich German chamomile chemistry rather than a rare trace compound.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2025 Bulgarian full-text study reported alpha-bisabolol oxide B at 10.8% in one German chamomile oil and 13.7% in another producer's sample.
The same study found stronger antioxidant performance in the German chamomile oils than in the Roman chamomile oils, but those activity results were measured for the complete oils.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2025/2026 abstracted nanoparticle and docking paper did not directly test isolated oxide B in cells, but it reported favorable in silico ADMET and docking results for oxide B alongside the oxide A work.
This is weak early-stage evidence and is better treated as a research lead than as verified constituent pharmacology.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Screening assumption (family fallback). It is not a verified constituent-specific exposure limit.
model fallback · Tisserand Institute — sesquiterpene alcohols/oxides generally regarded as low sensitization riskNo public constituent-specific safety monograph, dermal maximum, or dedicated irritation dataset was located for isolated alpha-bisabolol oxide B.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because public bioactivity claims around oxide B are mostly inferred from chamomile oil composition or grouped bisabolol-oxide discussion, copy should stay conservative and avoid overstating isolated-compound effects.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
predicted target binding in computational screens
A recent bisabolol oxide A-centered paper reported favorable docking and ADMET properties for bisabolol oxide B against beta-catenin and EGFR, but direct wet-lab validation for isolated oxide B was not demonstrated.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not verify an isolated-compound human or animal pharmacology paper focused primarily on bisabolol oxide B.
- Direct constituent-specific dermal, sensitization, and phototoxicity data for isolated oxide B were not located in the reviewed public sources.
- Most public biological discussion around oxide B remains mixture-level, grouped with other chamomile sesquiterpenes, or computational.
- No IFRA Standard, Tisserand monograph, or RIFM safety assessment specific to isolated alpha-Bisabolol oxide B (CAS 26184-88-3) was located; the IFRA Standard for alpha-Bisabolol (CAS 515-69-5, Amendment 49) applies to a structurally distinct parent alcohol, not this oxide, and is not used here as a constituent-specific limit.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.